The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms

Pharmacogenomics Journal

Volumn 7, Issue 4, 2007, Pages 266-274

  Robinson, J D ^a   Lam, C Y ^a   Minnix, J A ^a   Wetter, D W ^a   Tomlinson, G E ^b   Minna, J D ^c   Chen, T T L ^c   Cinciripini, P M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; NICOTINE PATCH; PLACEBO; PROSTEP NICOTINE PATCH; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; SELF REPORT; SHORT COURSE THERAPY; SMOKING CESSATION; SMOKING HABIT; SYMPTOMATOLOGY; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; SEVERITY OF ILLNESS INDEX; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 34547626815     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500427     Document Type: Article

References (43)

1. Wise RA, Rompre PP. Brain dopamine and reward. Ann Rev Psychol 1989; 40: 191-225.
2. Blum K, Noble EP, Sheridan PJ, Finley O, Montgomery A, Ritchie T et al. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 1991; 8: 409-416.
3. Comings DE, Comings BG, Muhlemann D. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991; 266 1793-1800.
4. O'Hara BF, Smith SS, Bird G, Persico AM, Suarez BK, Cutting GR et al. Dopamine D2 receptor RFLPs, haplotypes, and their association with substance use in Black and Caucasian research volunteers. Hum Hered 1993; 43: 209-218.
5. Hauge XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 1991; 10: 527-530.
6. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004; 23: 540-545.
7. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12: 205-216.
8. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577-582.
9. 2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991; 48: 648-654.
10. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-296.
11. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3: 256-260.
12. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine Tob Res 2004; 6: 583-597.
13. Li MD, Ma JZ, Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 2004; 66 382-392.
14. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking. Pharmacogenetics 1996; 6: 73-79.
15. Noble EP, St Jeor ST, Ritchie T, Syndulko RT, St Jeor SC, Fitch RJ et al. D2 dopamine receptor gene and cigarette smoking: A reward gene? Med Hypotheses 1994; 42: 257-260.
16. Spitz MR, Shi H, Hudmon KS, Jiang H, Chamberlain RM, Amos CI et al. A case-control study of the dopamine D2 receptor gene and smoking status in lung cancer. J Natl Cancer Inst 1998; 90: 358-363.
17. Pastorelli R, Bardazzi G, Saieva C, Cerri A, Gestri D, Allamani A et al. Genetic determinants of alcohol addiction and metabolism: A survey in Italy. Alcohol Clin Exp Res 2001; 25: 221-227.
18. Wu X, Hudmon KS, Detry MA, Chamberlain RM, Spitz MR. D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: A lung cancer case-control study. Cancer Epidemiol Biomarker Prevent 2000; 9: 1021-1026.
19. Bierut LJ, Rice JP, Edenberg HJ, Goate A, Foroud T, Cloninger CR et al. Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 2000; 90: 299-302.
20. Anokhin AP, Todorov AA, Madden PA, Grant JD, Heath AC. Brain event-related potentials, dopamine D2 receptor gene polymorphism, and smoking. Genet Epidemiol 1999; 17(Suppl 1): S37-S42.
21. Gilbert DG, McClemon FJ, Rabinovich NE, Sugai C, Plath LC, Asgaard G et al. Effects of quitting smoking on EEG activation and attention last for more than 31 days and are more severe with stress, dependence, DRD2 A1 allele, and depressive traits. Nicotine Tob Res 2004; 6 249-267.
22. Piasecki TM, Fiore MC, Baker TB. Profiles in discouragement: Two studies of variability in the time course of smoking withdrawal symptoms. J Abnorm Psychol 1998; 107: 238-251.
23. Piasecki TM, Niaura R, Shadel WG, Abrams DB, Goldstein M, Fiore MC et al. Smoking withdrawal dynamics in unaided quitters. J Abnorm Psychol 2000; 109: 74-86.
24. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers. J Abnorm Psychol 2003; 112: 3-13.
25. Prochaska JO, Velicer WF, Diclemente CC, Guadagnoli E, Rossi JS. Patterns of change: Dynamic typology applied to smoking cessation. Multivar Behav Res 1991; 26: 83-107.
26. Shiffman S, Paty J, Gnys M, Kassel J, Hickcox M. First lapses to smoking: Within-subjects analysis of real-time reports. J Consul Clin Psychol 1996; 64: 366-379.
27. Cinciripini PM, Wetter DW, Tomlinson GE, Tsoh JY, De Moor CA, Cinciripini LG et al. The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 2004; 6: 229-239.
28. Shiffman S, West R, Gilbert D. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res 2004; 6: 599-614.
29. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Smoking withdrawal dynamics: II. Improved tests of withdrawal-relapse relations. J Abnorm Psychol 2003; 112: 14-27.
30. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Smoking withdrawal dynamics: III. Correlates of withdrawal heterogeneity. Exp Clin Psychopharmacol 2003; 11: 276-285.
31. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS Scales. J Personal Soc Psychol 1988; 54: 1063-1070.
32. Welsch SK, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB. Development and validation of the Wisconsin smoking withdrawal scale. Exp Clin Psychopharmacol 1999; 7: 354-361.
33. Cinciripini PM, Tsoh JT, Wetter DW, Lam CY, De Moor CA, Cinciripini LG et al. Combined effects of venlafaxine, nicotine replacement & brief counseling on smoking cessation. Exp Clin Psychopharmacol 2005; 13: 282-292.
34. Cinciripini PM, Cinciripini LG, Seay S, Wallfisch A, Myer WJ, Van Vunakis H. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: Differences between high and low anxiety smokers. J Clin Psychopharmacol 1995; 15: 182-191.
35. Cinciripini PM, Cinciripini LG, Wallfisch A, Van Vunakis H, Haquè W. Behavior therapy and the transdermal nicotine patch: Effects on cessation outcome, affect, and coping. J Consul Clin Psychol 1996; 64: 314-323.
36. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. US Department of Health and Human Services: Rockville, MD, 2000.
37. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for Axis I DSM-IV Disorders, Patient Edition (SCID-II, version 2.0). Biometrics Research Department, New York State Psychiatric Institute: New York, 1994.
38. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
39. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43: 289-294.
40. McCullagh P, Nedler JA. Generalized Linear Models. 2nd edn, Whapman & Hall: NY, New York, 1989.
41. Gibbons R, Hedeker D, Waternaux C. Random regression models: A comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmocology 1988; 24: 438-443.
42. Gibbons R, Hedeker D, Elkin I, Waternaux C, Kraemer KH, Greehouse J et al. Some conceptual and statistical issues in the analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993; 50: 739-750.
43. Wright SP. Multivariate Analysis Using the MIXED Procedure. Proceedings of the 23rd Annual SAS Users Group International Conference, Paper 229. SAS Institute Inc.: Cary, NC, 1998.